深度观察|从“烧钱”走向“赚钱”,2025年中国创新药上市公司收入突破1000亿元,我们离全球“领跑”还差多远?

每日经济新闻
Apr 03

随着2025年各家上市公司年报密集出炉,中国创新药产业的结构性变革,正式浮出水面。《每日经济新闻》记者不完全统计,百济神州、信达生物、华领医药、诺诚健华、乐普生物、荣昌生物、迈博药业、北海康成等公司扭亏为盈。  创新药企终于从“烧钱”走向“赚钱”,与此同时,中国已跃升为全球创新药优质在研管线的核心供给地。国家药监局发布的最新数据显示,2026年一季度中国创新药对外授权交易总额已突破600亿美元,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10